These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30640753)

  • 1. A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer.
    Taylor CR; Jadhav AP; Gholap A; Kamble G; Huang J; Gown A; Doshi I; Rimm DL
    Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):263-269. PubMed ID: 30640753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
    Rimm DL; Han G; Taube JM; Yi ES; Bridge JA; Flieder DB; Homer R; West WW; Wu H; Roden AC; Fujimoto J; Yu H; Anders R; Kowalewski A; Rivard C; Rehman J; Batenchuk C; Burns V; Hirsch FR; Wistuba II
    JAMA Oncol; 2017 Aug; 3(8):1051-1058. PubMed ID: 28278348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis.
    Widmaier M; Wiestler T; Walker J; Barker C; Scott ML; Sekhavati F; Budco A; Schneider K; Segerer FJ; Steele K; Rebelatto MC
    Mod Pathol; 2020 Mar; 33(3):380-390. PubMed ID: 31527709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.
    Rehman JA; Han G; Carvajal-Hausdorf DE; Wasserman BE; Pelekanou V; Mani NL; McLaughlin J; Schalper KA; Rimm DL
    Mod Pathol; 2017 Mar; 30(3):340-349. PubMed ID: 27834350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer.
    Pan B; Kang Y; Jin Y; Yang L; Zheng Y; Cui L; Sun J; Feng J; Li Y; Guo L; Liang Z
    J Transl Med; 2021 Jun; 19(1):249. PubMed ID: 34098964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma.
    Liu J; Zheng Q; Mu X; Zuo Y; Xu B; Jin Y; Wang Y; Tian H; Yang Y; Xue Q; Huang Z; Chen L; Gu B; Hou X; Shen L; Guo Y; Li Y
    Sci Rep; 2021 Aug; 11(1):15907. PubMed ID: 34354151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer.
    Jasani B; Bänfer G; Fish R; Waelput W; Sucaet Y; Barker C; Whiteley JL; Walker J; Hovelinck R; Diezko R
    Diagn Pathol; 2020 Apr; 15(1):37. PubMed ID: 32303234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
    Del C Monroig-Bosque P; Driver B; Morales-Rosado JA; Deavers M; Tacha D; Bernicker E; Cagle PT; Miller RA
    Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation.
    Kim HN; Jang J; Heo YJ; Kim B; Jung H; Jang Y; Kang SY; Kim ST; Lee J; Kang WK; Kim KM
    Virchows Arch; 2020 Feb; 476(2):243-250. PubMed ID: 31463730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Deep Learning-Based Assay for Programmed Death Ligand 1 Immunohistochemistry Scoring in Non-Small Cell Lung Carcinoma: Does it Help Pathologists Score?
    Ito H; Yoshizawa A; Terada K; Nakakura A; Rokutan-Kurata M; Sugimoto T; Nishimura K; Nakajima N; Sumiyoshi S; Hamaji M; Menju T; Date H; Morita S; Bise R; Haga H
    Mod Pathol; 2024 Jun; 37(6):100485. PubMed ID: 38588885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
    Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting.
    Skov BG
    Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):49-55. PubMed ID: 31913160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interobserver agreement in programmed cell death-ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens.
    Sinclair W; Kobalka P; Ren R; Beshai B; Lott Limbach AA; Wei L; Mei P; Li Z
    Diagn Cytopathol; 2021 Feb; 49(2):219-225. PubMed ID: 33104298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated PD-L1 Scoring for Non-Small Cell Lung Carcinoma Using Open-Source Software.
    Naso JR; Povshedna T; Wang G; Banyi N; MacAulay C; Ionescu DN; Zhou C
    Pathol Oncol Res; 2021; 27():609717. PubMed ID: 34257575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
    Ilie M; Khambata-Ford S; Copie-Bergman C; Huang L; Juco J; Hofman V; Hofman P
    PLoS One; 2017; 12(8):e0183023. PubMed ID: 28797130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer.
    Cooper WA; Russell PA; Cherian M; Duhig EE; Godbolt D; Jessup PJ; Khoo C; Leslie C; Mahar A; Moffat DF; Sivasubramaniam V; Faure C; Reznichenko A; Grattan A; Fox SB
    Clin Cancer Res; 2017 Aug; 23(16):4569-4577. PubMed ID: 28420726
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.
    Russell-Goldman E; Kravets S; Dahlberg SE; Sholl LM; Vivero M
    Cancer Cytopathol; 2018 Apr; 126(4):253-263. PubMed ID: 29405663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non-Small Cell Lung Cancer.
    Song P; Guo L; Li W; Zhang F; Ying J; Gao S
    J Immunother; 2019 Jan; 42(1):23-28. PubMed ID: 30407231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Machine-learning-based image analysis algorithms improve interpathologist concordance when scoring PD-L1 expression in non-small-cell lung cancer.
    Haragan A; Parashar P; Bury D; Cross G; Gosney JR
    J Clin Pathol; 2024 Jan; 77(2):140-144. PubMed ID: 38071529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice.
    Villaruz LC; Ancevski Hunter K; Kurland BF; Abberbock S; Herbst C; Dacic S
    Histopathology; 2019 Jan; 74(2):269-275. PubMed ID: 30105871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.